Citadel Advisors
TYRA icon

Citadel Advisors’s Tyra Biosciences TYRA Stock Holding History

Citadel Advisors’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,600
Closed -$559K – 14881
2026
Q1 		$559K Buy
14,600
+2,100
+17% +$68K ﹤0.01% 9035
2025
Q4 		$329K Sell
12,500
-11,000
-47% -$202K ﹤0.01% 9946
2025
Q3 		$329K Buy
+23,500
New +$268K ﹤0.01% 10147
2025
Q2 		– Sell
-14,200
Closed -$132K – 15177
2025
Q1 		$132K Buy
14,200
+10,400
+274% +$135K ﹤0.01% 11064
2024
Q4 		$52.8K Sell
3,800
-17,800
-82% -$323K ﹤0.01% 12338
2024
Q3 		$508K Buy
+21,600
New +$453K ﹤0.01% 8230
2024
Q2 		– Sell
-600
Closed -$9.84K – 15441
2024
Q1 		$9.84K Buy
+600
New +$9.84K ﹤0.01% 13480
2023
Q1 		– Sell
-4,100
Closed -$31.2K – 15535
2022
Q4 		$31.2K Buy
+4,100
New +$29K ﹤0.01% 12700

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Citadel Advisors's TYRA Position: Q2 2026 in Review

Citadel Advisors increased its Tyra Biosciences (TYRA) stake by 1,708% in Q2 2026, buying an estimated $8.7M and bringing the position to 278,307 shares worth $8.89M. The position accounts for ﹤0.01% of the portfolio, ranked #3745.

Citadel Advisors first reported a position in TYRA in Q4 2021 and has held it in 13 quarters since. 168 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • Citadel Advisors held 278,307 shares of Tyra Biosciences worth $8.89M as of Q2 2026.
  • Citadel Advisors bought 262,911 Tyra Biosciences shares in Q2 2026, an estimated $8.7M.
  • Tyra Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3745 holding.
  • Citadel Advisors first reported a position in Tyra Biosciences in Q4 2021 and has held it in 13 quarters since.
  • 168 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.